Liu W, Li J, Tang Y, Zhao Y, Liu C, Song M
Nat Commun. 2025; 16(1):2256.
PMID: 40050282
PMC: 11885830.
DOI: 10.1038/s41467-025-57430-4.
He H, Wang L, Ma M
Cancer Innov. 2025; 4(2):e160.
PMID: 40026873
PMC: 11868734.
DOI: 10.1002/cai2.160.
Mareboina M, Bakhl K, Agioti S, Yee N, Georgakopoulos-Soares I, Zaravinos A
Biomedicines. 2025; 13(2).
PMID: 40002821
PMC: 11853441.
DOI: 10.3390/biomedicines13020408.
Patel A, Tong S, Roosan M, Syed B, Awasthi A, Silverman R
Cancers (Basel). 2025; 17(3).
PMID: 39941844
PMC: 11816268.
DOI: 10.3390/cancers17030477.
Zhong Y, Wang R, Huang Z, Hu Z, Peng B, Chen B
Immun Inflamm Dis. 2025; 13(1):e70126.
PMID: 39817582
PMC: 11736640.
DOI: 10.1002/iid3.70126.
Exploring glioma heterogeneity through omics networks: from gene network discovery to causal insights and patient stratification.
Kastendiek N, Coletti R, Gross T, Lopes M
BioData Min. 2024; 17(1):56.
PMID: 39696678
PMC: 11657291.
DOI: 10.1186/s13040-024-00411-y.
Topological embedding and directional feature importance in ensemble classifiers for multi-class classification.
Rocha Liedl E, Yassin S, Kasapi M, Posma J
Comput Struct Biotechnol J. 2024; 23:4108-4123.
PMID: 39624167
PMC: 11609472.
DOI: 10.1016/j.csbj.2024.11.013.
Reproducible processing of TCGA regulatory networks.
Fanfani V, Shutta K, Mandros P, Fischer J, Saha E, Micheletti S
bioRxiv. 2024; .
PMID: 39574772
PMC: 11580957.
DOI: 10.1101/2024.11.05.622163.
Cancer pharmacoinformatics: Databases and analytical tools.
Kamble P, Nagar P, Bhakhar K, Garg P, Sobhia M, Naidu S
Funct Integr Genomics. 2024; 24(5):166.
PMID: 39294509
DOI: 10.1007/s10142-024-01445-5.
A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies.
Li J, Liu W, Mojumdar K, Kim H, Zhou Z, Ju Z
Nat Cancer. 2024; 5(10):1579-1595.
PMID: 39227745
DOI: 10.1038/s43018-024-00817-x.
Bioinformatics tools and resources for cancer and application.
Huang J, Mao L, Lei Q, Guo A
Chin Med J (Engl). 2024; 137(17):2052-2064.
PMID: 39075637
PMC: 11374212.
DOI: 10.1097/CM9.0000000000003254.
A computational workflow for analysis of missense mutations in precision oncology.
Khan R, Pokorna P, Stourac J, Borko S, Arefiev I, Planas-Iglesias J
J Cheminform. 2024; 16(1):86.
PMID: 39075588
PMC: 11285293.
DOI: 10.1186/s13321-024-00876-3.
A prognostic matrix gene expression signature defines functional glioblastoma phenotypes and niches.
Vishnoi M, Dereli Z, Yin Z, Kong E, Kinali M, Thapa K
Res Sq. 2024; .
PMID: 38947019
PMC: 11213219.
DOI: 10.21203/rs.3.rs-4541464/v1.
Subtype-MGTP: a cancer subtype identification framework based on multi-omics translation.
Xie M, Kuang Y, Song M, Bao E
Bioinformatics. 2024; 40(6).
PMID: 38857453
PMC: 11194476.
DOI: 10.1093/bioinformatics/btae360.
Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis.
Sun T, Zhang P, Zhang Q, Wang B, Zhao Q, Liu F
Heliyon. 2024; 10(10):e30780.
PMID: 38765024
PMC: 11096979.
DOI: 10.1016/j.heliyon.2024.e30780.
Pan-cancer analysis of telomere maintenance mechanisms.
Hakobyan M, Binder H, Arakelyan A
J Biol Chem. 2024; 300(6):107392.
PMID: 38763334
PMC: 11225560.
DOI: 10.1016/j.jbc.2024.107392.
Exploring The Prognostic Significance of SET-Domain Containing 2 (SETD2) Expression in Advanced and Castrate-Resistant Prostate Cancer.
Gamallat Y, Lima J, Seyedi S, Li Q, Rokne J, Alhajj R
Cancers (Basel). 2024; 16(7).
PMID: 38611113
PMC: 11010867.
DOI: 10.3390/cancers16071436.
Deep learning infers clinically relevant protein levels and drug response in breast cancer from unannotated pathology images.
Liu H, Xie X, Wang B
NPJ Breast Cancer. 2024; 10(1):18.
PMID: 38413598
PMC: 10899601.
DOI: 10.1038/s41523-024-00620-y.
Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells.
Victorio C, Novera W, Ganasarajah A, Ong J, Thomas M, Wu J
J Transl Med. 2024; 22(1):126.
PMID: 38308299
PMC: 10835997.
DOI: 10.1186/s12967-024-04930-4.
KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA network.
Zhang M, Jiang L, Liu X, Liu F, Zhang H, Zhang Y
Heliyon. 2024; 10(1):e24287.
PMID: 38234923
PMC: 10792648.
DOI: 10.1016/j.heliyon.2024.e24287.